Cardlytics, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
CDLX$1.63-10.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
ITEM 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES
(a)The following documents are filed as part of this Annual Report:
(i)Consolidated Financial Statements and Reports of Independent Registered Public Accounting Firm are shown in the Index to Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
(ii)All financial statement schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.
(iii)Exhibits are incorporated herein by reference or are filed with this Annual Report as indicated below.
(b)Exhibits:
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit | Exhibit Description | Schedule/Form | FileNumber | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | S-1 | 333-222531 | 3.2 | 1/12/2018 |
| 3.2 | Amended and Restated Bylaws of the Registrant | S-1 | 333-222531 | 3.4 | 1/12/2018 |
| 4.1 | Form of Common Stock Certificate of the Registrant | S-1/A | 333-222531 | 4.1 | 1/29/2018 |
| 4.2 | Description of Cardlytics, Inc. Common Stock | 10-K | 001-38386 | 4.3 | 3/3/2020 |
| 4.3 | Indenture, dated as of April 1, 2024, by and between the Registrant ant U.S. Bank National Association, as Trustee. | 8-K | 001-38386 | 4.1 | 4/1/2024 |
| 4.4 | Form of Global Note, representing the Registrant’s 4.25% Convertible Senior Notes due 2029 (included as Exhibit A to the Indenture filed as Exhibit 4.6) | 8-K | 001-38386 | 4.2 | 4/1/2024 |
| 10.1 | Office Lease Agreement, dated as of August 5, 2013, by and between the Registrant and Jamestown Ponce City Market, L.P. | S-1 | 333-222531 | 10.12 | 1/12/2018 |
| 10.2† | 2008 Stock Plan and Forms of Option Agreement, Notice of Stock Option Grant, Exercise Notice, Restricted Stock Unit Notice and Restricted Stock Unit Agreement thereunder, as amended to date | S-1/A | 333-222531 | 10.1 | 1/29/2018 |
| 10.3† | 2018 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder | S-1/A | 333-222531 | 10.2 | 1/29/2018 |
| 10.4† | 2018 Employee Stock Purchase Plan | S-1/A | 333-222531 | 10.3 | 1/29/2018 |
| 10.5† | Form of restricted securities unit award of the Registrant under 2018 Equity Incentive Plan | S-1 | 333-222531 | 10.8 | 1/12/2018 |
| 10.6† | Form of Indemnity Agreement by and between the Registrant and each of its directors and executive officers | S-1 | 333-222531 | 10.9 | 1/12/2018 |
| 10.7^ | Master Agreement and Schedule #1 to the Master Agreement, dated May 3, 2018 and May 7, 2018, respectively, by and between the Company and JPMorgan Chase Bank, National Association | 10-Q | 001-38386 | 10.1 | 8/14/2018 |
| 10.8^ | 2018 Amendment to Schedule #1 to the Master Agreement, dated October 23, 2018, by and between the Registrant and JPMorgan Chase Bank, N.A. | 10-K | 001-38386 | 10.22 | 3/3/2020 |
| 10.9^ | Second Amendment to Schedule #1, dated June 4, 2020, among Cardlytics, Inc. and JPMorgan Chase Bank, National Association | 10-Q | 001-38386 | 10.1 | 8/4/2020 |
| 10.10 | Consent to Loan and Security Agreement, dated as of March 5, 2021, by and among Cardlytics, Inc., as Borrower, BSpears Merger Sub II, LLC, as additional borrower, and Pacific Western Bank, as Lender | 10-Q | 001-38386 | 10.1 | 5/4/2021 |
| 10.11^ | Agreement and Plan of Merger, dated April 12, 2021, by and among Cardlytics, Inc., Bridg, Inc., Mr. T Merger Sub, Inc., and Shareholder Representative Services LLC | 8-K | 001-38386 | 10.1 | 11/18/2022 |
| 10.12† | Severance Agreement between Nick Lynton and Cardlytics, Inc. | 10-Q | 001-38386 | 10.4 | 11/1/2022 |
| 10.13† | 2022 Inducement Plan | 10-Q | 001-38386 | 10.7 | 11/1/2022 |
| 10.14† | Form of option grant notice and agreement under 2022 Inducement Plan | 10-Q | 001-38386 | 10.8 | 11/1/2022 |
| 10.15† | Form of restricted stock unit grant notice and agreement under 2022 Inducement Plan | 10-Q | 001-38386 | 10.9 | 11/1/2022 |
| 10.16† | Offer Letter Agreement between Amit Gupta and Cardlytics, Inc. | 10-K | 001-38386 | 10.41 | 3/1/2023 |
| 10.17† | Severance Agreement between Amit Gupta and Cardlytics, Inc. | 10-K | 001-38386 | 10.41 | 3/1/2023 |
| 10.18† | Amendment to Inducement Plan | 10-K | 001-38386 | 10.41 | 3/1/2023 |
| 10.19^ | Amendment No. Two to Office Lease Agreement dated as of April 23, 2023, by and between the Registrant and Jamestown Ponce City Market, L.P., as amended to date | 10-Q | 001-38386 | 10.4 | 5/4/2023 |
| 10.20† | Second Amendment to Inducement Plan | S-8 | 001-38386 | 4.8 | 7/18/2023 |
| 10.21^ | Third Amendment to Schedule #1, dated June 29, 2023, to the Master Agreement by and between the Registrant and JPMorgan Chase Bank, N.A. | 10-Q | 001-38386 | 10.1 | 8/1/2023 |
| 10.22† | Offer Letter Agreement between Alexis DeSieno and the Registrant dated June 20, 2023 | 10-Q | 001-38386 | 10.2 | 8/1/2023 |
| 10.23† | Separation Pay Agreement between Alexis DeSieno and the Registrant, dated July 13, 2023. | 10-Q | 001-38386 | 10.3 | 8/1/2023 |
| 10.24 | Work Order between the Company and American Express Travel Related Services Company dated March 14, 2024 to Master Hosted Services Agreement | 10-Q | 001-38386 | 10.4 | 5/8/2024 |
| 10.25† | Offer Letter between Amit Gupta and the Registrant, dated August 21, 2024. | 10-Q | 001-38386 | 10.1 | 11/6/2024 |
| 10.26 | Amended and Restated Loan and Security Agreement dated as of September 30, 2024, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender | 10-Q | 001-38386 | 10.3 | 11/6/2024 |
| 10.27* | Assumption Agreement and First Amendment to Loan and Security Agreement, dated as of December 6, 2024, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender | 10-K | 001-38386 | 10.37 | 3/12/2025 |
| 10.28*^ | Assumption Agreement and Second Amendment to Loan and Security Agreement, dated as of January 27, 2025, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender | 10-K | 001-38386 | 10.38 | 3/12/2025 |
| 10.29 | Assumption Agreement and Third Amendment to Loan and Security Agreement, dated as of March 26, 2025, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender | 10-Q | 001-38386 | 10.2 | 5/7/2025 |
| 10.30 | Assumption Agreement and Fourth Amendment to Loan and Security Agreement, dated as of April 16, 2025, by and among Cardlytics, Inc., as Borrower and Banc of California, as Lender | 10-Q | 001-38386 | 10.3 | 5/7/2025 |
| 10.31† | 2025 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise, Stock Option Grant Notice, Restricted Stock Unit Notice and Restricted Stock Agreement thereunder | 10-Q | 001-38386 | 10.1 | 8/6/2025 |
| 10.32† | Amended Offer Letter between Amit Gupta and the Registrant, dated June 23, 2025 | 10-Q | 001-38386 | 10.3 | 8/6/2025 |
| 10.33† | Amended Separation Pay Agreement between Amit Gupta and the Registrant, dated June, 23, 2025 | 10-Q | 001-38386 | 10.4 | 8/6/2025 |
| 10.34 | Fourth Amendment to Schedule #1, dated July 7, 2025, among Cardlytics, Inc. and JPMorgan Chase Bank, National Association | 10-Q | 001-38386 | 10.5 | 8/6/2025 |
| 10.35*† | Non-Employee Director Compensation Plan As Amended & Restated February 17, 2026 | ||||
| 10.36*† | 2025 Bonus Plan of the Registrant | ||||
| 10.37*^ | Asset Purchase Agreement among Cardlytics, Inc., PAR Technology Corporation and DB SUB, LLC, dated as of January 23, 2026 | ||||
| 10.38*† | Offer Letter Agreement between David Evans and Cardlytics, Inc. | ||||
| 10.39*† | Separation Pay Agreement between David Evans and Cardlytics, Inc. | ||||
| 10.40* | Consent and Fifth Amendment to Amended and Restated Loan and Security Agreement | ||||
| 19.1 | Insider Trading Policy | 10-K | 001-38386 | 19.1 | 3/12/2025 |
| 21.1* | Subsidiaries of the Registrant | ||||
| 23.1* | Consent of Deloitte & Touche LLP, independent registered public accounting firm | ||||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 32.1** | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||
| 97.1 | Amended and Restated Policy for Recoupment of Incentive Compensation, adopted on October 2, 2023 | 10-K | 001-38386 | 97.1 | 3/14/2025 |
| 101.ins | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | ||||
| 101.sch | XBRL Taxonomy Schema With Embedded Linkbase Document | ||||
| 104.0 | Cover page formatted as Inline XBRL and contained in Exhibit 101 |
- Filed herewith
** Furnished herewith
^ Certain portions of this exhibit, indicated by asterisks, have been omitted pursuant to Item 601(b)(10) of Regulation S-K because the registrant has determined that the omitted information is (i) not material and (ii) the type of information that the registrant customarily and actually treats as proviate and confidential.
† Indicates management contract or compensatory plan
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.